GlassScriptPhysician profile
David C Baez
NPI 1407896830
$3,347.97
in general payments reported to CMS, 2019-2025
35 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $443 · 2021: $606 · 2022: $433 · 2023: $545 · 2024: $226 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $645.21 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $387.69 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $278.48 | 2019-2022 | |
| Novo Nordisk INC | $204.66 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $203.99 | 2019-2025 | |
| Astellas Pharma US INC | $195.56 | 2019-2023 | Myrbetriq, Veozah |
| Gilead Sciences, INC. | $152.95 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $115.02 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $109.94 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $107.06 | 2019-2023 | Steglatro, Belsomra, Gardasil 9 |
| Lilly USA, LLC | $93.13 | 2021-2024 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $80.46 | 2020-2022 | |
| Amgen INC. | $77.67 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Dexcom, INC. | $66.54 | 2023-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $62.77 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $61.22 | 2019 | |
| Hologic Sales and Service, LLC | $46.89 | 2020-2022 | |
| Glaxosmithkline, LLC. | $46.51 | 2021-2025 | Arexvy, Shingrix |
| Abbott Laboratories | $43.35 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $42.85 | 2019-2020 | |
| Mdd US Operations, LLC | $39.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.21 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.06 | 2019-2023 | Trulance, Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $27.01 | 2023 | |
| Amarin Pharma, INC. | $23.12 | 2019 | |
| Uswm, LLC | $19.85 | 2021 | |
| Indivior INC. | $19.20 | 2023 | Sublocade |
| Zimmer Biomet Holdings, INC. | $18.42 | 2020 | |
| Eisai INC. | $17.56 | 2020 | |
| Mannkind Corporation | $17.54 | 2022 | |
| Seqirus USA INC | $16.96 | 2019 | |
| Bardy Diagnostics, INC. | $16.89 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.93 | 2021 | |
| Inogen, INC. | $13.42 | 2022 | |
| Bioventus LLC | $13.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Baez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.